Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno, Via Ponte Don Melillo, 84084 Fisciano (SA), Italy.
Bioorg Med Chem. 2010 May 1;18(9):3252-60. doi: 10.1016/j.bmc.2010.03.022. Epub 2010 Mar 15.
In the course of our ongoing efforts to discover new and more effective HDAC inhibitors useful for the development of promising anticancer candidates, we have recently undertaken a molecular modelling study on a small collection of FR235222 analogues, synthesized by us in the frame of a structure-activity relationship investigation, made in order to identify the key structural elements essential for the activity. Progress made in structure elucidation of HDAC active site, together with accurate docking calculations, provided new structural insights useful for a further refinement of the tetrapeptide scaffold which should assure an optimal interaction between the synthetic ligands and the biological target. Following the computer aided suggestions we synthesized six new cyclotetrapeptide analogues of the lead compound (3-8), bearing a carboxylic or an hydroxamic acid functionality as Zn binding moiety. Herein we describe their synthesis and their inhibition activity on different HDAC isoforms.
在我们不断努力发现新的和更有效的 HDAC 抑制剂,以开发有前途的抗癌候选药物的过程中,我们最近对一小部分 FR235222 类似物进行了分子建模研究,这些类似物是我们在结构-活性关系研究框架内合成的,目的是确定对活性至关重要的关键结构元素。在阐明 HDAC 活性位点结构方面取得的进展,以及精确的对接计算,为进一步改进四肽支架提供了新的结构见解,这应该确保合成配体与生物靶标之间的最佳相互作用。根据计算机辅助建议,我们合成了先导化合物(3-8)的六个新的环四肽类似物,其作为 Zn 结合部分带有羧酸或羟肟酸官能团。本文描述了它们的合成及其对不同 HDAC 同工酶的抑制活性。